GE Healthcare will provide SPECT and PET radiopharmaceuticals to members of the HealthTrust group purchasing organization across the U.S.
The agreement went into effect on March 1 and covers approximately 1,600 acute-care facilities and HealthTrust members in more than 26,000 locations, including ambulatory surgery centers, physician practices, and long-term and alternate care sites.
HealthTrust member facilities will have access to GE Life Sciences' SPECT proprietary products such as Myoview and Ceretec, as well as non-GE Healthcare products such as methylene diphosphonate (MDP), indium-111, and thallium chloride.
